Expert council resolution on treatment of patients with metastatic colorectal cancer

1. Fedyanin M.Yu., Alieva Sh.A., Vladimirova L.Yu. et al. Quality of treatment for metastatic colon cancer in routine clinical practice. Zlokachestvennye opukholi = Malignant Tumors 2017;7(3 special issue 1):4–11. (In Russ.).

2. Kopetz S., Chang G.J., Overman M.J. et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27(22):3677–83. PMID: 19470929. DOI: 10.1200/JCO.2008.20.5278.

3. Adam R., Yi B., Innominato P.F. et al. Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients. Eur J Cancer 2017;78:7–15. PMID: 28407529. DOI: 10.1016/j.ejca.2017.03.009.

4. Adam R., ASCO 2012, abstract 3521.

5. Garufi C., Torsello A., Tumolo S. et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010;103(10):1542–7. PMID: 20959822. DOI: 10.1038/sj.bjc.6605940.

6. Folprecht G. et al. EMCC 2011, abstract 6009.

7. Köhne C.-H. et al. ASCO 2011, abstract 3576. 8. Modest D.P., Denecke T., Pratschke J. et al. Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancercentral evaluation of FIRE-3. Eur J Cancer 2018;88:77–86. PMID: 29195117. DOI: 10.1016/j.ejca.2017.10.028.

8. Stintzing S., Modest D.P., Rossius L. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): A post-hoc analysis of tumour dynamics in the final RAS wildtype subgroup of this randomised openlabel phase 3 trial. Lancet Oncol 2016;17(10):1426–34. PMID: 27575024. DOI: 10.1016/S1470-2045(16)30269-8.

9. Petrelli F., Ardito R., Ghidini A. et al. Different toxicity of cetuximab and panitumumab in metastatic colorectal cancer treatment: a systematic review and metaanalysis. Oncology 2018;94(4):191–9. PMID: 29393280. DOI: 10.1159/000486338.

10. Price T., Kim T.W., Li J. et al. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemo-refractory wildtype KRAS exon 2 metastatic colorectal cancer. Eur J Cancer 2016;68:51–9. PMID: 27716478. DOI: 10.1016/j.ejca.2016.08.010.

11. NCCN Guidelines v. 3, 2018. Colon cancer.